Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors.


Journal

Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213

Informations de publication

Date de publication:
03 03 2019
Historique:
received: 02 11 2018
accepted: 22 01 2019
entrez: 7 3 2019
pubmed: 7 3 2019
medline: 21 3 2020
Statut: epublish

Résumé

Background To compare the frequency of adverse events of thermal microwave (MWA) and radiofrequency ablation (RFA) with non-thermal irreversible electroporation (IRE) in percutaneous ablation of hepatocellular carcinoma (HCC). Patients and methods We retrospectively analyzed 117 MWA/RFA and 47 IRE procedures (one tumor treated per procedure; 144 men and 20 women; median age, 66 years) regarding adverse events, duration of hospital and intensive care unit (ICU) stays and occurrence of a post-ablation syndrome. Complications were classified according to the Clavien & Dindo classification system. Results 70.1% of the RFA/MWA and 63.8% of the IRE procedures were performed without complications. Grade I and II complications (any deviation from the normal postinterventional course, e.g., analgesics) occurred in 26.5% (31/117) of MWA/RFA and 34.0% (16/47) of IRE procedures. Grade III and IV (major) complications occurred in 2.6% (3/117) of MWA/RFA and 2.1% (1/47) of IRE procedures. There was no significant difference in the frequency of complications (p = 0.864), duration of hospital and ICU stay and the occurrence of a post-ablation syndrome between the two groups. Conclusions Our results suggest that thermal (MWA and RFA) and non-thermal IRE ablation of malignant liver tumors have comparable complication rates despite the higher number of punctures and the lack of track cauterization in IRE.

Identifiants

pubmed: 30840591
doi: 10.2478/raon-2019-0011
pii: raon-2019-0011
pmc: PMC6411026
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116-122

Commentaires et corrections

Type : ErratumIn

Références

Radiology. 2003 Feb;226(2):441-51
pubmed: 12563138
World J Gastroenterol. 2014 Apr 21;20(15):4115-27
pubmed: 24764650
Eur J Surg Oncol. 2018 May;44(5):651-657
pubmed: 29402556
Hepatol Res. 2015 Jan;45(2):
pubmed: 25625806
Dtsch Arztebl Int. 2014 Feb 14;111(7):101-6
pubmed: 24622679
Gut. 2003 May;52 Suppl 3:iii1-8
pubmed: 12692148
Radiology. 1998 Dec;209(3):761-7
pubmed: 9844671
Ann Biomed Eng. 2005 Feb;33(2):223-31
pubmed: 15771276
J Vasc Interv Radiol. 1998 Jan-Feb;9(1 Pt 1):101-11
pubmed: 9468403
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Vasc Interv Radiol. 2012 Jun;23(6):727-36
pubmed: 22513394
Orv Hetil. 2010 Jun 6;151(23):933-40
pubmed: 20494888
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Diagn Interv Radiol. 2015 Nov-Dec;21(6):471-5
pubmed: 26359870
Eur J Surg Oncol. 2017 Apr;43(4):751-757
pubmed: 28109674
HPB (Oxford). 2010 Jun;12(5):289-99
pubmed: 20590901
J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S293-5
pubmed: 14514836
Clin J Oncol Nurs. 2002 Mar-Apr;6(2):107-8
pubmed: 11889672
Australas Radiol. 2007 Dec;51(6):550-4
pubmed: 17958690
J Vasc Interv Radiol. 2014 Jan;25(1):97-105.e1-2
pubmed: 24286938
Eur Radiol. 2011 Dec;21(12):2584-96
pubmed: 21858539
AJR Am J Roentgenol. 2005 Jul;185(1):51-7
pubmed: 15972398
Tumori. 1999 Mar-Apr;85(2):128-32
pubmed: 10363079
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
AJR Am J Roentgenol. 2002 Jan;178(1):47-51
pubmed: 11756085
J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S377-90
pubmed: 19560026
Radiology. 2017 Dec;285(3):1023-1031
pubmed: 28799842
Ann Surg. 1998 Apr;227(4):559-65
pubmed: 9563546
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Indian J Palliat Care. 2016 Jan-Mar;22(1):67-73
pubmed: 26962283
Radiology. 2009 Jun;251(3):933-40
pubmed: 19304921
Technol Cancer Res Treat. 2017 Feb;16(1):120-124
pubmed: 27837054
Hepatol Res. 2010 Nov;40(11):1043-1059
pubmed: 34818831

Auteurs

Niklas Verloh (N)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Isabel Jensch (I)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Lukas Lürken (L)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Michael Haimerl (M)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Marco Dollinger (M)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Philipp Renner (P)

Department of Surgery, Robert-Bosch-Hospital, Stuttgart, Germany.

Philipp Wiggermann (P)

Department of Radiology, Hospital Braunschweig, Braunschweig Germany.

Jens Martin Werner (JM)

Department of Surgery, University Hospital Regensburg, Regensburg, Germany.

Florian Zeman (F)

Center for Clinical Trials, University Hospital Regensburg, Regensburg, Germany.

Christian Stroszczynski (C)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Lukas Philipp Beyer (LP)

Department of Radiology, University Hospital Regensburg, Regensburg Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH